AllSight
Companies · SGMT · Pharmaceutical Preparations

Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences Inc. (SGMT) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Sagimet Biosciences Inc. (SGMT) stock — financials & valuation

Key numbers for Sagimet Biosciences Inc. (SGMT): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 46/100 — a percentile rank of Sagimet Biosciences Inc.’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.

Market cap$582.4M
EV / EBITDA-7.9×
Return on equity-18.4%
ROIC-58.3%
Debt / equity0.0×
Dividend yield0.0%

Is Sagimet Biosciences Inc. overvalued? P/B looks fair vs its 5-year range.

Independent of the events above — derived from Sagimet Biosciences Inc.’s own financial statements and shown as context, never as advice.

Sep 30, 2026$107.5M financing
Sagimet Biosciences share offering raises $107.5M for acne trials but dilutes holders
Sep 30, 2026Above the bar
Sagimet acne trial shows durable 52-week gains ahead of U.S. Phase 3
Aug 13, 2026FDA IND cleared
Sagimet clears the FDA gate—but the real acne test is still ahead
Aug 11, 2026
U.S. acne Phase 3 stays on track, but no new catalyst
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact